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Propranolol administration enhances the GH re¬ sponse to several stimuli like hypoglycemia (10) , exercise (11) , glucagon (12) , and GHRH (13, 14) , probably through inhibition of endogenous SRIH secretion (15) (16) (17) . In test 2 ( Fig. 1) , propranolol pretreatment at -90 min did not influence basal GH secretion (from 1.7±2 at -90 min to 1.4±0.7 pg/1 at 0 min).
The first GHRH administration stimulated GH se¬ cretion to 25.5±19 pg/1 at 60 min, with a mean nAUC of2327± 1814 pg-l"'-(120 min)"1, which was significantly greater than in the control test (p<0.05) (Fig. 2) . The variability between the sub¬ jects was not modified ( (13, 14) despite the differ¬ ent route of administration of the ß-blocking drug. The variability of the GH responses to GHRH was not modified by pretreatment with the drug. As it is not clear whether the ß-adrenergic receptors in¬ volved in GH inhibition are of the ß, or ß2 subtype (14, 18) , we chose to use a nonspecific ß-selective (10) (11) (12) (13) (14) .
Two main mechanisms may be involved in the adrenergic modulation of the GH response to GHRH: direct action at the pituitary level and in¬ hibition of endogenous SRIH secretion. However, ß-adrenergic receptors present at the pituitary level have been shown to be stimulatory in in vitro stud¬ ies (19) (20) (21) , making the former hypothesis unlikely. On the other hand, several experimental ap¬ proaches in rats suggest that ß-adrenergic blockade diminishes hypothalamic SRIH secretion (15) (16) (17) . Since the ultradian rhythm of GH secretion is thought to derive from the interplay of GHRH and SRIH secretion (6, 22) (8) . In keeping with this hypothesis, Massara et al. (9) were able to restore the GH response to a second GHRH bolus by pretreatment with pyridostigmine, which acts by inhibiting endogenous SRIH secretion. Our data could also be explained by ß-blockade-induced decrease of somatostatinergic tone, even though the magnitude of the response is clearly lower than that reported with pyridostigmine. On the other hand, the loss of responsiveness to repeated GHRH stimulations is a multifactorial phenome¬ non in which cellular mechanisms also play an im¬ portant role, as demonstrated by in vitro studies showing both receptor desensitization and deple¬ tion of a GHRH-sensitive releasable pool (26) (27) (28) .
In conclusion, oral administration of proprano¬ lol 90 min before GHRH injection is able to en¬ hance the GH response, without changing the great heterogeneity of individual responses, and the response to repeated GHRH stimulation is only partially restored by ß-adrenergic blockade. Thus, it seems unlikely that a combined propranolol-GHRH test with these modalities could improve the diagnostic usefullness of GHRH testing in clin¬ ical practice.
